Search Result

Results for "

gallstone

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) Autophagy (1) Endogenous Metabolite (9) FXR (1) Isotope-Labeled Compounds (1) Somatostatin Receptor (1) Stearoyl-CoA Desaturase (SCD) (1)
By Research Areas:	Cardiovascular Disease (1) Inflammation/Immunology (3) Metabolic Disease (11)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-133707

β-Muricholic acid	Endogenous Metabolite	Metabolic Disease
β-Muricholic acid is a potent and orally active biliary cholesterol-desaturating agent. β-Muricholic acid prevents cholesterol gallstones. β-Muricholic acid inhibits lipid accumulation. β-Muricholic acid has the potential for the research of nonalcoholic fatty liver disease (NAFLD) .

HY-114360

Taurohyodeoxycholic acid 1 Publications Verification	Endogenous Metabolite	Metabolic Disease
Taurohyodeoxycholic acid is the tauroconjugated form of Hyodeoxycholic acid (HDCA, a dihydroxylated natural bile acid). Taurohyodeoxycholic acid induces a biliary phospholipid secretion and suggests a hepatoprotective potential. Taurohyodeoxycholic acid also can promote gallstone dissolution .

HY-W403933

12-Ketochenodeoxycholic acid	Autophagy	Metabolic Disease
12-Ketochenodeoxycholic acid 12 is a direct precursor of cholodeoxycholic acid (CDCA). Cholodeoxycholic acid is used to cholesterol gallstones and has chemotherapeutic properties that dissolve gallstones .

HY-126995

Glycohyodeoxycholic acid	Endogenous Metabolite	Metabolic Disease
Glycohyodeoxycholic acid is a major metabolite of Hyodeoxycholic acid in humans. Glycohyodeoxycholic acid has preventative effects on gallstone formation .

HY-133890A

Tauro-α-muricholic acid sodium 2 Publications Verification T-α-MCA sodium	Endogenous Metabolite FXR	Others
Tauro-α-muricholic acid (T-α-MCA) sodium is a FXR (Farnesoid X receptor) antagonist (IC₅₀=28μM). Tauro-α-muricholic acid sodium is also a endogenous metabolite that can be found in cecal .

HY-113212

Ursocholic acid 1 Publications Verification	Endogenous Metabolite Apoptosis	Metabolic Disease Inflammation/Immunology
Ursocholic acid, a bile acid present in mammalian bile, is converted to deoxycholic acid (UDC) by the mouse intestinal flora. Ursocholic acid acts as a gallstone dissolving agent in the liver through anti-apoptosis, anti-inflammatory, immunomodulatory, bile regulation, and coordinated changes in mitochondrial integrity and cell signaling, Ursocholic acid also has favorable effects on bones in patients with chronic cholestasis .

HY-126995R

Glycohyodeoxycholic acid (Standard)	Endogenous Metabolite	Metabolic Disease
Glycohyodeoxycholic acid (Standard) is the analytical standard of Glycohyodeoxycholic acid. This product is intended for research and analytical applications. Glycohyodeoxycholic acid is a major metabolite of Hyodeoxycholic acid in humans. Glycohyodeoxycholic acid has preventative effects on gallstone formation .

HY-118311

(Z)-W 3699 (Z)-Probilin; (Z)-Secrebil; (Z)-Piprozolin	Others	Metabolic Disease
(Z)-W 3699 is a potential choleretic. (Z)-W 3699 can increase the solubility of cholesterol in the gallbladder by altering the secretion of micellar bile acids. (Z)-W 3699 can prevent the formation of cholesterol-containing gallstones in dogs.

HY-133707R

β-Muricholic acid (Standard)	Endogenous Metabolite	Metabolic Disease
Deracoxib (Standard) is the analytical standard of Deracoxib. This product is intended for research and analytical applications. 0

HY-157303

SSTR5 antagonist 3	Somatostatin Receptor	Cardiovascular Disease
SSTR5 antagonist 3 (Compound 23) is an orally active somatostatin receptor subtype 5 (SSTR5) antagonist with low hERG inhibition. SSTR5 antagonist 3 exhibits potency with IC₅₀ values of 2.8 nM and 1.4 nM in human and mouse, respectively. SSTR5 antagonist 3 can be used for the research of anti-gallstone .

HY-19796

Icomidocholic acid 1 Publications Verification Aramchol; C20-FABAC	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease
Icomidocholic acid (Aramchol) is a lipid molecule synthesized from cholic acid and arachidic acid. Icomidocholic acid is an orally active SCD1 inhibitor and cholesterol solubilizer with antifibrotic effects. Icomidocholic acid can reduce liver fat content, dissolve cholesterol crystals and prevent gallstone formation. Icomidocholic acid can be used in the study of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) .

HY-113212S

Ursocholic acid-d4	Isotope-Labeled Compounds Apoptosis Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
Ursocholic acid-d₄ is deuterium labeled Ursocholic acid. Ursocholic acid, a bile acid present in mammalian bile, is converted to deoxycholic acid (UDC) by the mouse intestinal flora. Ursocholic acid acts as a gallstone dissolving agent in the liver through anti-apoptosis, anti-inflammatory, immunomodulatory, bile regulation, and coordinated changes in mitochondrial integrity and cell signaling, Ursocholic acid also has favorable effects on bones in patients with chronic cholestasis .

HY-113212R

Ursocholic acid (Standard)	Endogenous Metabolite Apoptosis	Metabolic Disease Inflammation/Immunology
Ursocholic acid (Standard) is the analytical standard of Ursocholic acid. This product is intended for research and analytical applications. Ursocholic acid, a bile acid present in mammalian bile, is converted to deoxycholic acid (UDC) by the mouse intestinal flora. Ursocholic acid acts as a gallstone dissolving agent in the liver through anti-apoptosis, anti-inflammatory, immunomodulatory, bile regulation, and coordinated changes in mitochondrial integrity and cell signaling, Ursocholic acid also has favorable effects on bones in patients with chronic cholestasis[1][2][3][4][5].

Cat. No.	Product Name

HY-L087

Anti-Obesity Compound Library	2,906 compounds
Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries. MCE Anti-Obesity Compound Library owns a unique collection of 2,906 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

Anti-Obesity Compound Library

2,906 compounds

Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries.

MCE Anti-Obesity Compound Library owns a unique collection of 2,906 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-133707

β-Muricholic acid	Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
β-Muricholic acid is a potent and orally active biliary cholesterol-desaturating agent. β-Muricholic acid prevents cholesterol gallstones. β-Muricholic acid inhibits lipid accumulation. β-Muricholic acid has the potential for the research of nonalcoholic fatty liver disease (NAFLD) .

HY-114360

Taurohyodeoxycholic acid 1 Publications Verification	Structural Classification Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite
Taurohyodeoxycholic acid is the tauroconjugated form of Hyodeoxycholic acid (HDCA, a dihydroxylated natural bile acid). Taurohyodeoxycholic acid induces a biliary phospholipid secretion and suggests a hepatoprotective potential. Taurohyodeoxycholic acid also can promote gallstone dissolution .

HY-W403933

12-Ketochenodeoxycholic acid	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Autophagy
12-Ketochenodeoxycholic acid 12 is a direct precursor of cholodeoxycholic acid (CDCA). Cholodeoxycholic acid is used to cholesterol gallstones and has chemotherapeutic properties that dissolve gallstones .

HY-126995

Glycohyodeoxycholic acid	Structural Classification Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite
Glycohyodeoxycholic acid is a major metabolite of Hyodeoxycholic acid in humans. Glycohyodeoxycholic acid has preventative effects on gallstone formation .

HY-133890A

Tauro-α-muricholic acid sodium 2 Publications Verification T-α-MCA sodium	Structural Classification Classification of Application Fields Source classification Other Diseases Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite FXR
Tauro-α-muricholic acid (T-α-MCA) sodium is a FXR (Farnesoid X receptor) antagonist (IC₅₀=28μM). Tauro-α-muricholic acid sodium is also a endogenous metabolite that can be found in cecal .

HY-113212

Ursocholic acid 1 Publications Verification	Structural Classification Microorganisms Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite Apoptosis
Ursocholic acid, a bile acid present in mammalian bile, is converted to deoxycholic acid (UDC) by the mouse intestinal flora. Ursocholic acid acts as a gallstone dissolving agent in the liver through anti-apoptosis, anti-inflammatory, immunomodulatory, bile regulation, and coordinated changes in mitochondrial integrity and cell signaling, Ursocholic acid also has favorable effects on bones in patients with chronic cholestasis .

HY-126995R

Glycohyodeoxycholic acid (Standard)	Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Glycohyodeoxycholic acid (Standard) is the analytical standard of Glycohyodeoxycholic acid. This product is intended for research and analytical applications. Glycohyodeoxycholic acid is a major metabolite of Hyodeoxycholic acid in humans. Glycohyodeoxycholic acid has preventative effects on gallstone formation .

HY-133707R

β-Muricholic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Endogenous Metabolite
Deracoxib (Standard) is the analytical standard of Deracoxib. This product is intended for research and analytical applications. 0

HY-113212R

Ursocholic acid (Standard)	Structural Classification Microorganisms Source classification Endogenous metabolite Steroids	Endogenous Metabolite Apoptosis
Ursocholic acid (Standard) is the analytical standard of Ursocholic acid. This product is intended for research and analytical applications. Ursocholic acid, a bile acid present in mammalian bile, is converted to deoxycholic acid (UDC) by the mouse intestinal flora. Ursocholic acid acts as a gallstone dissolving agent in the liver through anti-apoptosis, anti-inflammatory, immunomodulatory, bile regulation, and coordinated changes in mitochondrial integrity and cell signaling, Ursocholic acid also has favorable effects on bones in patients with chronic cholestasis[1][2][3][4][5].

Cat. No.	Product Name	Chemical Structure

HY-113212S

Ursocholic acid-d4
Ursocholic acid-d₄ is deuterium labeled Ursocholic acid. Ursocholic acid, a bile acid present in mammalian bile, is converted to deoxycholic acid (UDC) by the mouse intestinal flora. Ursocholic acid acts as a gallstone dissolving agent in the liver through anti-apoptosis, anti-inflammatory, immunomodulatory, bile regulation, and coordinated changes in mitochondrial integrity and cell signaling, Ursocholic acid also has favorable effects on bones in patients with chronic cholestasis .

Ursocholic acid-d4

Ursocholic acid-d₄ is deuterium labeled Ursocholic acid. Ursocholic acid, a bile acid present in mammalian bile, is converted to deoxycholic acid (UDC) by the mouse intestinal flora. Ursocholic acid acts as a gallstone dissolving agent in the liver through anti-apoptosis, anti-inflammatory, immunomodulatory, bile regulation, and coordinated changes in mitochondrial integrity and cell signaling, Ursocholic acid also has favorable effects on bones in patients with chronic cholestasis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

gallstone

Inhibitors & Agonists

Screening Libraries

NaturalProducts

Isotope-Labeled Compounds

Natural
Products